牛牛AI助理已提取核心訊息
On December 31, 2023, a Schedule 13G was filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a collective beneficial ownership of 9.8% of Zyversa Therapeutics, Inc.'s common stock. This group, consisting of investment advisors and directors from Texas and Ontario, Canada, has shared voting and dispositive power over 160,671 shares of the biopharmaceutical company. The filing, which was completed on February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Zyversa Therapeutics. The Schedule 13G is a regulatory document required by the SEC when parties exceed certain thresholds of ownership in a company's stock.
On December 31, 2023, a Schedule 13G was filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a collective beneficial ownership of 9.8% of Zyversa Therapeutics, Inc.'s common stock. This group, consisting of investment advisors and directors from Texas and Ontario, Canada, has shared voting and dispositive power over 160,671 shares of the biopharmaceutical company. The filing, which was completed on February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Zyversa Therapeutics. The Schedule 13G is a regulatory document required by the SEC when parties exceed certain thresholds of ownership in a company's stock.
2023年12月31日，安森基金管理有限責任公司、安森管理集團有限責任公司、託尼·摩爾、安森顧問公司、阿明·納索和莫茲·卡薩姆向美國證券交易委員會提交了附表13G，表示擁有Zyversa Therapeutics, Inc.9.8％的集體實益所有權。”s 普通股。該小組由來自加拿大德克薩斯州和安大略省的投資顧問和董事組成，對這家生物製藥公司的160,671股股票共享投票權和處置權。該文件於2024年2月14日完成，聲稱這些股票是在正常業務過程中收購的，不是爲了改變或影響Zyversa Therapeutics的控制權。附表13G是當各方超過公司股票所有權的特定門檻時美國證券交易委員會要求的監管文件。
2023年12月31日，安森基金管理有限責任公司、安森管理集團有限責任公司、託尼·摩爾、安森顧問公司、阿明·納索和莫茲·卡薩姆向美國證券交易委員會提交了附表13G，表示擁有Zyversa Therapeutics, Inc.9.8％的集體實益所有權。”s 普通股。該小組由來自加拿大德克薩斯州和安大略省的投資顧問和董事組成，對這家生物製藥公司的160,671股股票共享投票權和處置權。該文件於2024年2月14日完成，聲稱這些股票是在正常業務過程中收購的，不是爲了改變或影響Zyversa Therapeutics的控制權。附表13G是當各方超過公司股票所有權的特定門檻時美國證券交易委員會要求的監管文件。
有用
沒用